|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.65 CAD | -0.68% |
|
-0.68% | +15.08% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 168M 119M 103M 96.45M 88.6M 11.33B 169M 1.14B 445M 5.66B 447M 438M 18.77B | P/E 2026 * |
16.5x | P/E 2027 * | 13.6x |
|---|---|---|---|---|---|
| Enterprise Value | 168M 119M 103M 96.45M 88.6M 11.33B 169M 1.14B 445M 5.66B 447M 438M 18.77B | EV / Sales 2026 * |
2.43x | EV / Sales 2027 * | 2.04x |
| Free-Float |
64.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 day | -0.68% | ||
| 1 week | -0.68% | ||
| Current month | -0.68% | ||
| 1 month | +1.03% | ||
| 3 months | +1.74% | ||
| 6 months | +4.64% | ||
| Current year | +15.08% |
| 1 week | 14.65 |  | 14.75 |
| 1 month | 14.42 | | 14.75 |
| Current year | 12.25 | | 15.8 |
| 1 year | 10.65 | | 15.8 |
| 3 years | 7.55 | | 15.8 |
| 5 years | 6.24 | | 15.8 |
| 10 years | 3.13 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/30/26 | Tax | Executive/Senior Manager | -11,359 | 0.0993% | ||
| 6/30/26 | Option | Chief Technology Officer | -600 | 0.0052% | ||
| 6/30/26 | Buy | Chief Technology Officer | -1,884 | 0.0165% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.68% | -0.68% | +28.73% | +94.04% | 119M | |
| -0.51% | -8.60% | +45.08% | +148.21% | 995B | |
| +0.20% | -4.42% | +49.05% | +50.81% | 614B | |
| -0.53% | -7.37% | +23.64% | +65.03% | 431B | |
| +1.17% | -0.11% | +41.46% | +36.42% | 353B | |
| +0.77% | -3.31% | +31.39% | +39.61% | 293B | |
| +3.49% | -7.46% | +8.32% | +11.65% | 245B | |
| -5.43% | -14.27% | -5.26% | -46.89% | 210B | |
| +2.94% | -0.78% | +29.17% | +60.32% | 210B | |
| +3.13% | +0.69% | +18.11% | +71.90% | 168B | |
| Average | +0.48% | -4.59% | +26.97% | +53.11% | 351.84B | |
| Weighted average by Cap. | +1.61% | -5.89% | +33.85% | +70.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 49.06M 42.6M 39.71M 36.48M 4.67B 69.76M 468M 183M 2.33B 184M 180M 7.73B | 82.3M 58.51M 50.81M 47.37M 43.52M 5.57B 83.2M 558M 218M 2.78B 220M 215M 9.22B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-04 | $14.65 | -0.68% | 46,242 |
| 26-07-31 | $14.75 | +0.61% | 3,743 |
| 26-07-29 | $14.66 | -0.61% | 1,258 |
| 26-07-28 | $14.75 | +0.07% | 1,810 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.65CAD
Average target price
18.00CAD
Spread / Average Target
+22.87%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Select your edition
All financial news and data tailored to specific country editions
